Pyxis Oncology

Our President and CEO, Lara S. Sullivan, M.D., will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10 at 2:20 PM ET. A webcast and replay of the fireside chat will be available on the Events and Presentations section of our website, pyxisoncology.com.

Important milestone for #PYXS! The FDA has granted Fast Track Designation to PYX-201 monotherapy for patients with recurrent or metastatic head and neck cancer. This recognition highlights the urgent need for new treatment options and the potential of PYX-201 to make a meaningful impact. Read full press release here: https://lnkd.in/e2sWyJ9U #PyxisOncology #PYXS #ADC #AntibodyDrugConjugate #FDA #FastTrack #HeadandNeckCancer

Exciting progress at #PYXS! We’re thrilled to announce the initiation of a new combination trial for PYX-201, alongside expansion cohorts in our ongoing PYX-201 monotherapy trial. These milestones mark important steps in our mission to develop innovative therapies for patients with advanced solid tumors. Read full press release here: https://lnkd.in/ewU2f24A #PyxisOncology #PYXS #ADC #AntibodyDrugConjugate #SolidTumors

Hear from Glenn Hanna, M.D. who recently sat down with OncLive to discuss #PYXS encouraging recent positive preliminary data from our ongoing Phase 1 dose escalation study in PYX-201 in #HeadAndNeckCancer and other tumor types. Read here: https://bit.ly/4f6nRaR #HNSCC

Today #PYXS announced positive preliminary Phase 1 dose escalation data for PYX-201 in multiple types of solid tumors. Read the press release here: https://lnkd.in/e3bedaQG These results will be discussed at an investor event this afternoon at 4:30 pm. Register for the webcast here: https://bit.ly/4e97No8 "These positive data represent a significant milestone for Pyxis Oncology as our novel ECM-targeting ADC, PYX-201, has demonstrated clinical responses by RECIST 1.1 in six tumor types of interest: HNSCC, ovarian, NSCLC, HR+/HER2- breast, TNBC, and Sarcoma. The breadth and depth of our clinical responses clearly indicate the potential of PYX-201 to provide meaningful clinical benefits to patients with difficult-to-treat cancers," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. #ADC #AntibodyDrugConjugate #HeadAndNeckCancer #HNSCC #OvarianCancer #LungCancer #NSCLC #BreastCancer #Sarcoma

Only two days remain until #PYXS hosts an in-person and virtual event to discuss preliminary dose escalation data from our ongoing Phase 1 clinical trial evaluating PYX-201 in multiple types of solid tumors. The event will take place on Wednesday, November 20, 2024, at 4:30 p.m. ET at Venue 42 by Convene, located at 5 Times Square in New York City and via webcast. Save your spot to attend here: https://bit.ly/4e97No8

Today, #PYXS reported our Q3 2024 financial results and provided a corporate update. Read more: https://lnkd.in/eiXSRcYh

#PYXS will host an in-person and virtual event to discuss preliminary dose escalation data from the ongoing Phase 1 clinical trial evaluating PYX-201 in multiple types of solid tumors. The event will take place on Wednesday, November 20, 2024, at 4:30 p.m. ET at Venue 42 by Convene, located at 5 Times Square in New York City. Mark your calendars and register to attend live or virtually here: https://bit.ly/4e97No8

Today, we announced that our President and CEO, Lara S. Sullivan, M.D., will participate in fireside chats and members of management will host one-on-one meetings at two upcoming conferences. Please read our full press release for details, including replay information for our fireside chats. ir.pyxisoncology.com #PYXS

Today, #PYXS reported our Q2 2024 financial results and provided a corporate update. Read more: https://lnkd.in/eBYMAc5c